Literature DB >> 22169462

Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002.

J Faivre1, A Trama, R De Angelis, M Elferink, S Siesling, R Audisio, J F Bosset, A Cervantes, C Lepage.   

Abstract

BACKGROUND AND AIMS: Little is known about the epidemiology of rare epithelial digestive cancers. The aim of this study was to report on their incidence, prevalence and survival across Europe.
METHODS: The analysis was carried out on 50,646 cases diagnosed from 1995 to 2002 within a population of 162,000,000 in 21 European countries. Age-standardised incidence rates were computed using the European standard population. Prevalence rates, relative survival and period survival indicators for the years 2000-2002 were calculated. The expected number of new cases per year and of prevalent cases in Europe was estimated.
RESULTS: There were large variations in gallbladder epithelial cancer incidence rates: the incidence in Eastern Europe was 7 times higher than in the UK & Ireland. Differences between incidence rates were smaller for the other sites. The estimated number of new epithelial cancers arising in the EU each year was estimated to be 11,050 for extrahepatic bile duct cancer, 10,713 for gallbladder cancer, 5427 for anal cancer and 3595 for small intestine cancer. The corresponding estimated number of total prevalent cases was 18,483, 15,620, 40,589 and 13,276. There was also a large variation in the 5-year relative survival rate. For epithelial cancer of the anal canal, this varied between 66% (Central Europe) and 44% (Eastern Europe). The corresponding rates for small intestine cancers were 33% and 20%, for extrahepatic bile duct cancers, 17% and 12% and for gallbladder cancer 13% and 10%.
CONCLUSION: There are large variations within Europe in the incidence and survival of rare digestive cancers according to geographic area.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22169462     DOI: 10.1016/j.ejca.2011.10.038

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

Review 1.  Management of Advanced Small Bowel Cancer.

Authors:  Alberto Puccini; Francesca Battaglin; Heinz-Josef Lenz
Journal:  Curr Treat Options Oncol       Date:  2018-11-05

2.  Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5.

Authors:  L A Anderson; A Tavilla; H Brenner; S Luttmann; C Navarro; A T Gavin; B Holleczek; B T Johnston; M B Cook; F Bannon; M Sant
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

3.  Intestinal Obstruction of Uncommon Cause and Point-of-Care Ultrasonography - Where Do We Stand?

Authors:  Tiago Capela; Paula Sousa; Ana Caldeira; Eduardo Pereira
Journal:  GE Port J Gastroenterol       Date:  2017-07-14

4.  Dietary Polyunsaturated Fat Intake in Relation to Head and Neck, Esophageal, and Gastric Cancer Incidence in the National Institutes of Health-AARP Diet and Health Study.

Authors:  Shawn A Zamani; Kathleen M McClain; Barry I Graubard; Linda M Liao; Christian C Abnet; Michael B Cook; Jessica L Petrick
Journal:  Am J Epidemiol       Date:  2020-10-01       Impact factor: 4.897

Review 5.  Epidemiology of esophageal cancer.

Authors:  Yuwei Zhang
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

6.  Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience.

Authors:  Khurum Khan; Clare Peckitt; Francesco Sclafani; David Watkins; Sheela Rao; Naureen Starling; Vikram Jain; Sachin Trivedi; Susannah Stanway; David Cunningham; Ian Chau
Journal:  BMC Cancer       Date:  2015-01-21       Impact factor: 4.430

7.  Interstitial high-dose rate brachytherapy as boost for anal canal cancer.

Authors:  Alexander Tuan Falk; Audrey Claren; Karen Benezery; Eric François; Mathieu Gautier; Jean-Pierre Gerard; Jean-Michel Hannoun-Levi
Journal:  Radiat Oncol       Date:  2014-11-06       Impact factor: 3.481

8.  A Patient with Duodenal Mucinous Adenocarcinoma Presenting as a Laterally Spreading Tumor.

Authors:  Myung Joon Chae; Il Hyun Baek; Yu Mi Oh; Jun Uk Lim; Jung Won Jeon; Hyun Phil Shin; Kwang Ro Joo; Joung Il Lee
Journal:  Clin Endosc       Date:  2015-07-24

9.  Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study.

Authors:  T Aparicio; M Svrcek; A Zaanan; E Beohou; A Laforest; P Afchain; Emmanuel Mitry; J Taieb; F Di Fiore; J-M Gornet; A Thirot-Bidault; I Sobhani; D Malka; T Lecomte; C Locher; F Bonnetain; P Laurent-Puig
Journal:  Br J Cancer       Date:  2013-11-05       Impact factor: 7.640

10.  The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study.

Authors:  Hiroyuki Sakae; Hiromitsu Kanzaki; Junichiro Nasu; Yutaka Akimoto; Kazuhiro Matsueda; Masao Yoshioka; Masahiro Nakagawa; Shinichiro Hori; Masafumi Inoue; Tomoki Inaba; Atsushi Imagawa; Masahiro Takatani; Ryuta Takenaka; Seiyu Suzuki; Toshiyoshi Fujiwara; Hiroyuki Okada
Journal:  Br J Cancer       Date:  2017-10-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.